Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer by Holten-Andersen, M N et al.
Matrix metalloproteinases (MMPs) play a pivotal role in cancer
growth and spread, contributing to enzymatic degradation of the
integrity of the extracellular matrix (Liotta et al, 1991; Stetler-
Stevenson et al, 1993; MacDougall and Matrisian, 1995). The
naturally occurring inhibitors of MMPs – tissue inhibitors of
MMPs (TIMPs) form tight 1:1 stoichiometric complexes with the
activated forms of the MMPs (Welgus et al, 1985; Kleiner et al,
1993) thereby inhibiting the catalytic activity of these enzymes
(Goldberg et al, 1992; Birkedal-Hansen et al, 1993; Stetler-
Stevenson et al, 1996). In support of a protective role of TIMP-1
and TIMP-2 it was found that in vitro invasiveness (Khokha et al,
1992a; Khokha and Waterhouse, 1993) and metastatic spread of
tumour cells in experimental animal models (DeClerck et al, 1992;
Khokha et al, 1992b) was inhibited by transfection of cancer cells
with the genes encoding either TIMP-1 or TIMP-2. While the
balance between the matrix-degrading properties of MMPs and
the inhibitory effect of TIMPs is closely regulated under normal
physiological conditions (Matrisian, 1992; Birkedal-Hansen et al,
1993; Thorgeirsson et al, 1993), this balance might be disrupted in
malignant tissue.
A number of enzyme-linked immunoassays (ELISAs) for
detection of TIMP-1 (Kodama et al, 1989; Cooksley et al, 1990;
Clark et al, 1991) and TIMP-2 (Fujimoto et al, 1993) have been
reported. These assays have been applied to various forms of
bodily fluids, e.g. serum, plasma, amniotic fluid, cerebrospinal
fluid and urine, but the number of samples tested has not been
sufficient to establish normal ranges for the plasma level of the
TIMPs in healthy individuals (Kodama et al, 1989; Clark et al,
1991). Furthermore, recovery of specific signal from clinical
samples has not been demonstrated with internal standards.
In a study by Mimori et al (1997) in which tumour tissue levels
of TIMP-1 mRNA were studied in patients with gastric carcinoma,
high tumour/normal tissue ratios of TIMP-1 mRNA were found to
be associated with increased invasion and poor prognosis. ELISA
studies of free TIMP-1 in serum from prostate cancer patients
(Baker et al, 1994), and TIMP-1 in complex with MMP-9 in
plasma from patients with gastrointestinal cancer and gynaecolog-
ical cancer (Zucker et al, 1995), have demonstrated that the
inhibitor, free or in complex, was found in significantly higher
levels in blood samples from cancer patients and that patients with
high levels of TIMP-1:MMP-9 complex had a shorter survival
(Zucker et al, 1995). However, in a study of cervical carcinomas
(Nuovo et al, 1995), an increased ratio between expression of
MMP-2 and MMP-9 mRNAs and expression of TIMP-1 and
TIMP-2 mRNAs was found to be associated with poor survival,
suggesting that there may be an excess of MMP activity over
TIMP-1 in cancers with a poor prognosis. Similar results were
obtained by Gohji et al (1996), who showed that high MMP-
2:TIMP-2 protein ratios measured in serum from urothelial cancer
patients were related to poor patient outcome.
The goal of the present study was to develop further and
validate rigorously one of the previously described TIMP-1
ELISAs when applied to blood samples obtained from healthy
donors and cancer patients. Furthermore, this assay was used to
Quantitation of TIMP-1 in plasma of healthy blood
donors and patients with advanced cancer
MN Holten-Andersen1, G Murphy2, HJ Nielsen4, AN Pedersen1,3, IJ Christensen1, G Høyer-Hansen1, N Brünner1 and
RW Stephens1
1The Finsen Laboratory, Copenhagen University Hospital, Strandboulevarden 49, 2100 Copenhagen, Denmark; 2Strangeways Laboratories, Cambridge
University, Cambridge, UK; 3Department of Oncology, Herlev Hospital, Herlev Ringvej, 2730 Herlev, Denmark; 4Department of Gastroenterology, Hvidovre
Hospital, Kettegårds Alle, 2650 Hvidovre, Denmark
Summary A kinetic enzyme-linked immunosorbent assay (ELISA) for plasma tissue inhibitor of metalloproteinase (TIMP)-1 was developed in
order to examine the potential diagnostic and prognostic value of TIMP-1 measurements in cancer patients. The ELISA enabled specific
detection of total TIMP-1 in EDTA, citrate and heparin plasma. The assay was rigorously tested and requirements of sensitivity, specificity,
stability and good recovery were fulfilled. TIMP-1 levels measured in citrate plasma (mean 69.2 ± 13.1 mg l–1) correlated with TIMP-1
measured in EDTA plasma (mean 73.5 ± 14.2 mg l–1) from the same individuals in a set of 100 healthy blood donors (Spearman’s rho = 0.62,
P < 0.0001). The mean level of TIMP-1 in EDTA plasma from 143 patients with Dukes’ stage D colorectal cancer was 240 ± 145 mg l–1 and a
Mann–Whitney test demonstrated a highly significant difference between TIMP-1 levels in healthy blood donors and colorectal cancer
patients (P < 0.0001). Similar findings were obtained for 19 patients with advanced breast cancer (mean 292 ± 331 mg l–1). The results show
that TIMP-1 is readily measured in plasma samples by ELISA and that increased levels of TIMP-1 are found in patients with advanced cancer.
It is proposed that plasma measurements of TIMP-1 may have value in the management of cancer patients.
Keywords: TIMP-1; ELISA; plasma; cancer; blood donors
495
British Journal of Cancer (1999) 80(3/4), 495–503
© 1999 Cancer Research Campaign
Article no. bjoc.1998.0384
Received 16 June 1998
Revised 28 September 1998
Accepted 22 October 1998
Correspondence to: RW Stephensestablish reference ranges for TIMP-1 levels in donor plasma. It
was shown that healthy donors (n = 194) have a low, and very
narrow, range of plasma TIMP-1 levels, while patients with
advanced Dukes’ stage D colorectal cancer or breast cancer
present a diverse scatter of plasma TIMP-1 levels, significantly
elevated above the levels found in plasma from blood donors.
MATERIALS AND METHODS
Blood donors and patients
Through the cooperation of the blood bank at the Hvidovre
University Hospital, Copenhagen, blood samples were initially
obtained from 94 volunteer blood donors, comprising 51 males
aged 19–59 years (median 41 years) and 43 females aged 20–64
years (median 36 years). In a later collection, 100 donor samples
were obtained, comprising 56 males aged 19–59 years (median
42 years) and 44 females aged 20–60 years (median 36.5 years).
The donors presented voluntarily at a blood collection centre
where normal exclusion criteria applied, and the samples were
therefore considered as representing individuals in apparently
normal health. In addition, blood was collected from 19 stage IV
breast cancer patients (aged 45–70 years) at the Oncology
Department, Herlev University Hospital, Copenhagen, and from
143 Dukes’ stage D colorectal cancer patients (aged 36–88 years,
median 67 years, 60% were male) at the Department of Surgical
Gastroenterology, Hvidovre University Hospital, Copenhagen.
Informed consent was obtained from all blood donors and patients,
and permission was obtained from the local Ethical Committee.
Blood collections and plasma separation
Peripheral blood was drawn with minimal stasis (if necessary a
maximum of 2-min stasis with a tourniquet at maximum +2 kPa
was accepted) into prechilled citrate, EDTA, or heparin collection
tubes (Becton-Dickinson, Mountain View, CA, USA), mixed by
5 times inversion, and immediately chilled on ice. As soon as
possible (no later than 1.5 h after collection) the plasma was
separated from blood cells by centrifugation at 4°C at 1200 g for
30 min, and stored frozen at –80°C prior to assay. Plasma pools
were made with freshly collected samples from at least ten donors,
aliquoted and stored frozen at –80°C. When analysed, the samples
were thawed quickly in a water bath at 37°C and placed on ice
until the 1:100 plasma dilutions were made.
TIMP-1 ELISA
A sensitive and specific sandwich ELISA was developed, using
TIMP-1 antibodies developed at the Strangeways Laboratories
(Hembry et al, 1985). A sheep polyclonal anti-TIMP-1 antibody
(Hembry et al, 1985; Murphy et al, 1991) was used for catching, a
murine monoclonal anti-TIMP-1 IgG1 (MAC-15) (Cooksley et al,
1990) for detection of the antigen, and a rabbit anti-mouse
immunoglobulins–alkaline phosphatase conjugate (Dako,
Glostrup, Denmark) enabled kinetic rate assay. The latter conju-
gate was supplied preabsorbed against human IgG, thus avoiding
cross-reaction with IgG in the plasma samples. As the monoclonal
detection antibody MAC-15 recognizes both free TIMP-1 and
TIMP-1 in complex with MMPs (Cooksley et al, 1990), the total
TIMP-1 content of the measured sample captured by the sheep
polyclonal anti-TIMP-1 antibody (Hembry et al, 1985) was
determined by the ELISA.
Immunoassay plates (96-well) (Maxisorp, Nunc, Roskilde,
Denmark) were coated for 1 h at 37°C with 100 ml per well of
polyclonal sheep anti-TIMP-1 (4 mg l–1) in 0.1 mol l–1 carbonate
buffer, pH 9.5. Then the assay wells were rinsed twice with 200 ml
per well of SuperBlockTM solution (Pierce Chemicals, Rockford,
IL, USA) diluted 1:1 with phosphate-buffered saline (PBS). The
immunoassay plates were stored for up to 14 days at –20°C. On
the day of use the plates were thawed at room temperature and
washed five times in PBS containing 1 g l–1 Tween-20. Wells were
then treated for 1 h at 30°C with 100 ml per well of triplicate 1:100
dilutions of plasma made in a sample buffer consisting of
50 m mol l–1 phosphate, pH 7.2, 0.1 mol l–1 sodium chloride
(NaCl), 10 g l–1 bovine serum albumin (Fraction V, Boehringer-
Mannheim, Penzberg, Germany) and 1 g l–1 Tween-20. On every
assay plate the first three columns of wells (each column
consisting of eight wells) were incubated with a series of stan-
dards, consisting of seven serial dilutions in triplicate of purified
recombinant human TIMP-1, starting at 10 mg l–1 then 5, 2.5, 1.25,
0.625, 0.313 and 0.156 mg 1–1. Also included on each plate were
triplicate blank wells containing only sample dilution buffer, and
two sets of triplicate wells of a 1:100 dilution of a control citrate
plasma pool; the first set of triplicate plasma pool was added as the
first sample to the assay plate and the second set of triplicate
plasma pool was added as the last. After TIMP-1 binding, the
wells were washed five times, then treated for 1 h at 30°C with
100 ml per well of the purified murine monoclonal anti-TIMP
MAC-15 (0.5 mg l–1) in sample dilution buffer. After another five
washes, the wells were incubated for 1 h at 30°C with 100 ml per
well of rabbit anti-mouse immunoglobulins–alkaline phosphatase
conjugate diluted 1:2000 in sample dilution buffer. Following five
washes with washing solution and three washes with pure water,
100 ml of freshly made p-nitrophenyl phosphate (Sigma, St Louis,
MO, USA) substrate solution (1.7 g l–1 in 0.1 mol l–1 Tris-HCl, pH
9.5, 0.1 mol l–1 NaCl, 5 mmol l–1 magnesium chloride) was added
to each well and the plate was placed in a Ceres 900TM plate reader
(Bio-Tek Instruments, Winooski, VT, USA). The yellow colour
development at 23°C was monitored automatically, with readings
taken at 405 nm against an air blank every 10 min for 60 min.
KinetiCalc II software was used to manage the data, calculate the
rate of colour change for each well (linear regression analysis) and
compute from the rates for the TIMP-1 standards a 4-parameter
fitted standard curve, from which the TIMP-1 concentration of
each plasma sample was calculated.
Recovery experiments
The recovery of signal from standard TIMP-1 was measured after
addition to 1:100 dilutions of citrate, EDTA or heparin plasma
pools. Standard TIMP-1 was added to these plasma pool solutions
to give final concentrations in the range 0–10 mg l–1. The recovery
in each case was calculated from the slope of the line representing
TIMP-1 signal as a function of concentration, where 100%
recovery was defined as the slope obtained when TIMP-1 was
diluted in the sample dilution buffer.
Immunoblotting
Citrate plasma from a patient with a high level of TIMP-1 in blood
(634 mg l–1, determined by ELISA) was diluted 1:10 and added to
a column of protein A-Sepharose containing polyclonal sheep
anti-TIMP-1. Following five times recycling, bound proteins were
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electrophoresis of 50 ml of the resulting eluate was carried out
using a 12% acrylamide Ready GelTM (Bio-Rad). A total of 15 ml
of a mixture of low molecular weight (Pharmacia) and high mole-
cular weight markers (Bio-Rad) and 50 ml of TIMP-1 standard
(100 mg l–1) in Laemmli Sample BufferTM were also run on the gel.
Proteins were transferred electrophoretically from the gel onto a
polyvinylidene diflouride membrane (Millipore). The membrane
was incubated for 1 h at room temperature with 1% skimmed milk
powder in TBS. After washing, the membrane was incubated for
1 h at room temperature with 20 ml of MAC-15 at a concentration
of 5 mg l–1, followed by washing and incubation for another hour at
room temperature with 20 ml of rabbit anti-mouse immuno-
globulins–alkaline phosphatase conjugate diluted 1:1000. Finally
the membrane was washed and phosphate substrate solution
(NBT/BCIP) was added to develop colour.
RESULTS
ELISA performance
Development of colour in each well was a linear function of time
for all concentrations of TIMP-1 measured in these experiments
(Figure 1), with correlation coefficients for the automatically fitted
lines typically better than 0.99. The standard curve for the rates
plotted against the TIMP-1 concentration consisted of the linear
and upper curved regions (over the range 0–5 mg l–1) of a sigmoidal
curve, and the correlation coefficient for the four-parameter fit was
typically better than 0.999 (Figure 2). The rate with no TIMP-1
(read against air) was 1.21 ± 0.15 (mean ± standard deviation
(s.d.)) milliabsorbance units per min (n = 29), while the rate with
10 mg l–1 standard TIMP-1 was 50.3 ± 6.01 milliabsorbance units
per min (n = 29). The limit of detection for the assay, defined as the
concentration of TIMP-1 corresponding to a signal 3 s.d. above the
mean for the TIMP-1 blank, was 0.089 mg l–1 or 13% of the mean
of the measured concentration of TIMP-1 in healthy citrate plasma
samples diluted 1:100. The intra-assay coefficient of variation for
16 replicates of a control citrate plasma pool measured on the same
plate was 5.3%, and the inter-assay coefficient of variation for 29
successive assays of the plasma pool (on different days) was 6.2%.
This plasma pool had a TIMP-1 content of 57.8 mg l–1, corre-
sponding to the 22nd centile of the plasmas subsequently
measured.
Recovery of recombinant TIMP-1 after dilution in
plasma
Specific signal recovery was determined by addition of increasing
concentrations of purified TIMP-1 standard to a fixed 1:100 dilu-
tion of plasma pool and subsequent measurement of the ELISA
signal. In diluted citrate plasma pool 104% recovery was obtained,
101% in diluted EDTA plasma pool and 87% in diluted heparin
plasma pool (Figure 3). Thus, the recovery of TIMP-1 signal from
an internal standard was acceptable for all preparations of plasma,
but recovery from EDTA and citrate plasma was more complete
than heparin plasma.
Dilution curves for plasma TIMP-1 signal
Serial dilutions of citrate, EDTA and heparin plasma pools were
made and TIMP-1 levels assayed to test for linear reduction in
TIMP-1 levels in plasma 497
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Figure 1 Kinetic ELISA for TIMP-1. Progress curves for the change in
absorbance at 405 nm produced by hydrolysis of p-nitrophenyl phosphate by
solid-phase bound alkaline phosphatase immunoconjugate. The data shown
were generated by four individual assay wells treated with four different
concentrations of purified recombinant TIMP-1; 10 mg l–1 (t t), 2.5 mg l–1 (s s),
0.63 mg l–1 (n n) and 0.16 mg l–1 (l l). The lines shown have been fitted by
simple linear regression
Figure 2 TIMP-1 standard curve. ELISA-well absorbance measurements
for triplicate TIMP-1 standards in the range 0.0–5 mg 1–1 were collected
automatically over 60 min, with readings taken at 405 nm every 10 min.
Progress curves were computed for each assay well and the rates thus
obtained were fitted to a standard curve using a four-parameter equation of
the form y = d + [(a2d)/(1 + (x/c)b)]. In the example shown, the four derived
parameters had the following values: a = 1.87, b = 1.11, c = 3.35, d = 73.5.
The correlation coefficient for the fitted curve was > 0.999ELISA signal. Citrate, EDTA and heparin plasmas all gave
good linearity of signal as a function of dilution. The 1% plasma
dilution that was chosen for subsequent determinations lay well
within the range of this linear dilution curve.
Immunoblotting of plasma TIMP-1
The Western blot of the immunoabsorbed patient plasma sample
showed a clear band of 28 kDa (Figure 4, lane 2), corresponding to
free, uncomplexed TIMP-1 (Figure 4, lane 1). No bands were
found at the expected higher molecular weights corresponding to
complexes between MMPs and TIMP-1, e.g. MMP-2:TIMP-1,
100 kDa. This could indicate either that the majority of TIMP-1
was present in the plasma as the free form, or that complexes were
dissociated during SDS polyacrylamide gel electrophoresis (SDS-
PAGE). Although the sample was left both unreduced and
unheated in order to preserve any complexes present in the plasma
sample, it has been reported that MMP:TIMP complexes may be
unstable in SDS-PAGE (Stetler-Stevenson et al, 1989; Wilhelm et
al, 1989; Moll et al, 1990), even under non-reducing SDS-PAGE
conditions (Moutsiakis et al, 1992).
TIMP-1 in citrate and EDTA plasma from the same
healthy donors
A collection of citrate and EDTA plasma samples taken simultane-
ously from 100 healthy donors was available for this study. These
samples were not specifically collected as platelet-poor plasma.
However, when seven blood samples were prepared both as
platelet-poor plasma and as protocol plasma, no significant differ-
ence was found in their TIMP-1 levels (data not shown), so that
platelet TIMP-1 contamination of plasma in the present study was
considered insignificant. The percentile plots for TIMP-1 levels
determined in these samples are shown in Figure 5A. The values in
each set approximated a normal distribution; the citrate plasma
TIMP-1 levels had a reference range (10th to 90th centile) of
55.0–90.3 mg l–1 and a mean of 69.2 ± 13.1 mg l–1. Similarly, the
reference range for the EDTA plasma TIMP-1 levels was from
58.0 to 91.8 mg l–1 and the mean was 73.5 ± 14.2 mg l–1. For both
citrate and EDTA plasma the mean TIMP-1 levels lay in close
proximity to the median levels (Table 1). A paired means compar-
ison showed that the level of TIMP-1 in citrate plasma was signif-
icantly lower by 4.34 mg1 –1 (95% confidence interval (CI)
2.34–6.33;  P < 0.0001) than the level in EDTA plasma from the
same individual. However, it is likely that this reflected the differ-
ence in sampling procedure when collecting EDTA and citrate
plasma from the donors. EDTA plasma tubes contained dry anti-
coagulant material, while citrate plasma tubes contained a small
amount of liquid citrate buffer which gave a small and variable
systematic dilution error (´ 9/10). The level of TIMP-1 in citrate
plasma correlated with EDTA plasma from the same individuals:
the linear regression plot in Figure 5B shows a regression coeffi-
cient of 0.99 and the slope of the fitted line is 0.93, illustrating the
small dilution error. A non-parametric Spearman’s rank test for the
data set gave a rho value of 0.62 and P < 0.0001.
TIMP-1 levels in citrate plasma
In total, 194 citrate plasma samples from healthy blood donors
were assayed, comprising 94 samples taken from one collection
and 100 samples taken 9 months later from a different set of
donors. Figure 6 shows the percentile plots for TIMP-1 levels
measured in these two independent groups. The reference range
(10th to 90th centile) for TIMP-1 levels in citrate plasma from the
first collection was 53.3–77.7 mg l–1 with a mean TIMP-1 level of
65.4 ± 10.1 mg l–1 which was indistinguishable from the median
(Table 1); the values approximating a normal distribution. The
mean TIMP-1 level for the second collection was 69.2 ± 13.1 mg
l–1 (reference range 55.0–90.3 mg l–1). An unpaired means compar-
ison showed that TIMP-1 levels measured in the two sets of citrate
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Figure 3 Recovery of ELISA signal from standard TIMP-1 added in
increasing concentration to assay dilution buffer (n n), a 1:100 dilution of
EDTA plasma pool (s s), a 1:100 dilution of citrate plasma pool (t t) and a
1:100 dilution of heparin plasma pool (l l). The values shown are the means
of triplicates. The correlation coefficient for each fitted curve was greater than
0.99
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Figure 4 Western blotting of immunoabsorbed patient plasma sample.
Lane 1: standard TIMP-1; lane 2: eluate of patient citrate plasma sample
diluted 1:10 and immunoabsorbed with sheep polyclonal anti-TIMP-1. Bands
of unreduced standard TIMP-1 and TIMP-1 isolated from plasma sample
both appear just below 30 kDa.plasma samples taken in the two different collections differed only
by 3.82 mg l–1 (95% CI 0.50–7.14 mg l–1; P = 0.024). Moreover, no
significant difference was apparent between the plasma pool
controls (n = 8) included in each set of assays (mean difference
0.36 mg l–1; 95% CI – 1.71–2.44; P = 0.69). The mean TIMP-1
level for the total material of 194 citrate plasma samples was
67.3  ± 11.8 mg l–1, which was close to the median of 66.1 mg l–1, the
levels approximating a normal distribution (reference range
54.0–82.7 mg l–1).
Tests for correlations to gender and age of the donor
In the series of assays performed to obtain these results, the
interassay variation for the control plasma value was 2.7%.
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Figure 5 (A) Percentile plot for the level of TIMP-1 (mg l–1) measured by ELISA in citrate plasma (l l) and EDTA plasma (s s) from the same individual in a set of
100 volunteer blood donors. (B) Linear regression plot for the level of TIMP-1 in citrate plasma samples compared with EDTA plasma samples from the same
100 individuals. The equation of the fitted line is y = 0.93x, with a regression coefficient of 0.99Percentiles for TIMP-1 levels in 194 citrate plasma samples
divided according to gender are shown in Figure 7. The mean
TIMP-1 value for 107 male donors was 70.4 ± 12.0 mg l–1 (median
69.4 mg l–1) with a reference range (10th to 90th centile) from 56.2
to 86.6 mg l–1, while the mean TIMP-1 value for 87 female donors
in this set was 63.5 ± 10.5 mg l–1 (median 62.0 mg l–1) with the
reference range from 51.8 to 77.0 mg l–1. There was a significant
difference (P < 0.0001) in TIMP-1 mean levels between the two
groups; males were higher by 6.91 mg l–1 than females (95% CI
3.67–10.14 mg l–1, unpaired means comparison). There was a
relatively weak association between plasma TIMP-1 and age
(Spearman’s rho = 0.33), which was significant (P = 0.0011). This
did not show any gender specificity, and was weak for both
females (Spearman’s rho = 0.29, P = 0.006) and males
(Spearman’s rho = 0.35, P = 0.0003). In the EDTA plasma donor
material the mean TIMP-1 value for 56 males was 76.9 ± 15.0 mg
l–1 (median 75.1 mg l–1) with a reference range from 58.8 to 96.9 mg
1–1, while 44 female donors had a mean TIMP-1 plasma level of
69.3 ± 11.8 mg l–1 (median 67.9) with a reference range from 56.1
to 85.5 mg l–1. Again, a significant difference in TIMP-1 means
appeared between males and females, with males higher than
females by 7.53 mg l–1 (95% CI 2.04–13.0; P = 0.0076, unpaired
means comparison).
TIMP-1 levels in plasma from patients with advanced
cancer
TIMP-1 was measured in EDTA plasma samples from 143 patients
with Dukes’ stage D colorectal cancer, and a mean TIMP-1 level
of 240 ± 145 mg l–1 and a median value of 193 mg 1–1 were found
(reference range 106–451 mg l–1). Compared to EDTA plasma
samples from 100 healthy donors, a highly significant difference
in TIMP-1 plasma levels (P < 0.0001, Mann–Whitney) was
apparent between colorectal cancer patients and healthy donors.
Ninety per cent of the colorectal cancer patients in this study had
TIMP-1 plasma values that were above the 95th centile of TIMP-1
levels in donor plasma samples (Figure 8). While the cancer
patients, especially those with colorectal cancer, were older than
the control populations, the increase in TIMP-1 with age is consid-
ered too weak to account for the greatly increased levels found in
the cancer patients. In fact, the correlation between TIMP-1 level
and age of the colorectal cancer patients was weaker (rho = 0.18)
than for the donors (rho = 0.33), indicating that their disease was
the dominant factor contributing to the increase in their plasma
level of TIMP-1.
In a pilot study including 19 breast cancer patients with stage IV
disease, TIMP-1 levels in patient and healthy female donor citrate
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Table 1 Summary of TIMP-1 levels found in blood from healthy donors
Blood Date of Number of Mean ± s.d. Median Reference rangea
fraction sampling samples (mg l–1)( mg l–1)( mg l–1)
Citrate plasma Sept 1996 94 65.4 ± 10.1 65.6 53.3–77.7
Citrate plasma May 1997 100b 69.2 ± 13.1 67.0 55.0–90.3
Citrate plasma 1996 + 1997 194 67.3 ± 11.8 66.1 54.0–82.7
EDTA plasma May 1997 100b 73.5 ± 14.2 71.2 58.0–91.8
aThe reference range is defined as between the 10th and 90th percentiles. bThese samples were collected from the same donors.
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Figure 6 Percentile plot for the level of TIMP-1 (mg l–1) measured by ELISA in two sets of citrate plasma samples obtained by the same procedure from
volunteer blood donors at different times: 100 samples from May 1997 (s s) and 94 samples from Sept 1996 (n n)plasma were compared. The mean TIMP-1 level measured in
the citrate plasma samples from the 19 breast cancer patients was
292 ± 331 mg l–1 (median 236 mg l–1) compared to a mean TIMP-1
level of 63.5 ± 10.5 mg l–1 (median 62.0 mg l–1) in citrate plasma
samples from 87 healthy female donors with a reference range of
51.8–77.0 mg l–1. Bearing in mind the limited amount of patient
data in this comparison, a Wald–Wolfowitz runs test indicated a
highly significant difference with P < 0.0001 between patient
TIMP-1 levels and those of healthy donors.
DISCUSSION
The assay described above enabled accurate determination of total
TIMP-1 in human plasma samples. Detection of captured TIMP-1
with MAC-15 was conveniently followed by incubation with a
rabbit anti-mouse immunoglobulins–alkaline phosphatase conju-
gate, which allowed kinetic rate assays of the bound antigen. This
permitted automated fitting of rate curves which has proven
considerably more reliable than single end point measurements.
The use of a rapid blocking agent and a dilution buffer with high
buffering capacity also facilitated reproducible assays. Including
these elements in the final assay, requirements of sensitivity, speci-
ficity, stability and good recovery of an internal standard were
fulfilled.
The quantitative studies of TIMP-1 in blood from healthy
donors showed that both citrate and EDTA plasma samples are
suitable for the ELISA determination. Compared to other
published ELISA studies of TIMP-1 in healthy donors’ plasma
(Fung et al, 1996; Jung et al, 1996), the levels of TIMP-1 found in
the present study fell within a very narrow range. Some studies
have reported values for serum, but plasma was selected for the
present study to avoid the variable contribution of platelet activa-
tion to the measured TIMP-1 values (Cooper et al, 1985). While
the plasma samples used in this study were not specifically
prepared as platelet-poor plasma we do not anticipate, from tests
we have done, that this would significantly change the values
measured. The donor material was large enough to show that
TIMP-1 levels in healthy plasma (both EDTA and citrate) approx-
imated a normal distribution, for females as well as for males. For
both EDTA and citrate plasma, the mean TIMP-1 levels were
approximately 10% higher in males than in females. It could be
speculated that the reason for these higher levels of inhibitor in the
blood of males is a higher release rate of TIMP-1 into blood from
activated platelets, reflecting a tendency towards higher incidence
of thromboembolic disease amongst the male population. When
the males and females were considered separately, there was a
weak correlation between TIMP-1 level and age as seen for the
whole population (see above).
The remodelling of tissue which characterizes numerous
physiological as well as pathological events, e.g. wound healing,
trophoblast invasion, mammary gland involution, malignant
tumour invasion and metastasis, is well known to employ the
matrix-degrading abilities of the MMPs (Matrisian, 1992; Stetler-
Stevenson et al, 1996). Several studies of human cancers have
TIMP-1 levels in plasma 501
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Figure 7 Percentile plot for the level of TIMP-1 (mg l–1) measured by ELISA in 194 citrate plasma samples from volunteer blood donors and divided by gender
into 107 males (s s) and 87 females (l l)shown increased expression of MMPs in the tumour tissue
(De Nictolis et al, 1996; Kawano et al, 1997), but also increased
expression of the inhibitors of MMPs (TIMP-1 and TIMP-2)
(Fong, 1996; Yoshiji et al, 1996). ELISA studies of free TIMP-1 in
serum from prostate cancer patients have demonstrated that the
inhibitor is significantly increased in these patients (Baker et al,
1994). Increased plasma levels of MMP-9:TIMP-1 complex have
been found in patients with gastrointestinal cancer and gynaeco-
logical cancer (Zucker et al, 1995). These findings could imply
that growth and metastatic spread of malignant tumours neces-
sarily involves a higher level of activation of the MMP system
with a concomitant or compensatory increase in TIMP expression.
In this context, it is noteworthy that TIMP-1 has been found to
have a growth-promoting effect on both normal and malignant
cells (Hayakawa et al, 1992). Similarly, increased levels of the
type 1 inhibitor of plasminogen activator (PAI-1) are now associ-
ated with poor prognosis in several types of cancer (Frandsen et al,
1998), suggesting that PAIs, and perhaps also TIMPs may them-
selves be involved in the progression of cancer through a mecha-
nism independent of their anti-proteolytic activity (Deng et al,
1996).
The ELISA described above was applied to plasma samples
from patients with Dukes’ stage D colorectal cancer and patients
with advanced breast cancer, and it was found that in both cancer
types, plasma TIMP-1 was significantly increased as compared to
donor plasma levels. It is especially noteworthy that, in the 143
colorectal cancer patients, 90% of the patients had plasma TIMP-1
levels that were above the 95th centile of the plasma TIMP-1
levels in the donor plasmas, suggesting a potential application of
plasma TIMP-1 measurements in screening for colorectal cancer.
Moreover, since the results from the colorectal cancer and the
breast cancer study suggest that increased plasma TIMP-1 levels
may be a common feature of patients with advanced cancer, it
should therefore be investigated whether plasma TIMP-1 could be
useful as a marker of tumour recurrence. Finally, since high TIMP-
1 mRNA levels in cancer tissue and high TIMP-1 protein level in
plasma have been associated with poor survival of cancer patients,
it is suggested that measurement of TIMP-1 in blood of cancer
patients be further evaluated for its value as a prognostic marker.
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Figure 8 Plasma TIMP-1 levels (mg l–1) determined by ELISA in blood samples from patients with Dukes’ stage D colorectal cancer. In 143 EDTA plasma
samples from patients with Dukes’ stage D disease (l l), TIMP-1 levels were measured and compared with levels found in EDTA plasma samples from 100
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